1 Jan 2004 Jahr - FDA approves first "anti-angiogenic" drug, bevacizumab
Beschreibung:
Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.
Zugefügt zum Band der Zeit:
Cancer Dates
Datum:
